Clinical pharmacology studies in UK Phase 1 units: an AHPPI survey 1999-2000.
OBJECTIVE
This study, conducted by the Association for Human Pharmacology in the Pharmaceutical Industry (AHPPI), was designed to determine the amount of Phase 1 activity in the UK in the period 1999-2000, the timelines involved for submissions to ethics committee and responses from ethics committees.


METHODS
A questionnaire was completed by AHIPPI members from pharmaceutical companies with in-house phase 1 units, by Clinical Research Organizations (CRO's) and by academic centres. A few responses were also vailable from organisations that were not AHPPI members. Results were rendered anonymous and grouped by category.


RESULTS
The response rate was > 98% and indicated that the vast majority of early drug research in humans is now CRO-based (82%). The total number of studies (as indicated by protocol numbers) was notably similar across the 2 years--629 in 1999 and 606 in 2000. Turnaround time for ethics committee review was a mean of 14 days.


CONCLUSIONS
These data set important benchmarks for early-phase drug research in the UK where regulatory approval is not currently required. Furthermore, the information should be used as a guide if the competitive nature of such work in the UK is to be maintained as new national legislation is implemented following publication of the European Union (EU) Clinical Trials Directive.
Calder
N
N
Clinical Pharmacology, Merck Sharp and Dohme, Harlow, UK.
Boyce
M
M
Posner
J
J
Sciberras
D
D
D035843:Biomedical Research; D017321:Clinical Trials, Phase I as Topic; D004345:Drug Industry / Q000941:ethics*; D028741:Ethics Committees, Clinical; D028744:Ethics Committees, Research; D006801:Humans; D010601:Pharmacology, Clinical / Q000941:ethics*; D011795:Surveys and Questionnaires; D006113:United Kingdom